A distribution contract has been struck between preclinical molecular imaging system manufacturer Sedecal headquartered in Spain and United Kingdom radiation oncology systems manufacturer Xstrahl Life Sciences, the company announced today.

An investigational immune-PET biomarker maps tumor vasculature while skipping healthy tissues, according to a study published Feb. 13 in the Journal of Nuclear Medicine.

Following radiation therapy with chemotherapy has now been shown to prolong survival for glioma patients. Results of the study were announced Feb. 3 by the National Institutes of Health.

The Scottish developer of optical molecular imaging technology, Edinburgh Molecular Imaging, has received venture capital funding amounting to more than $6 million, the University of Edinburgh announced Feb 7.

Adrenoceptor blockers have been found to stave off metastasis and recurrence of breast cancer. This may be due to their interruption of key genes involved in glucose metabolism as visualized by FDG-PET, according to a study published Feb. 6 in the Journal of Nuclear Medicine.

PET/MR doesn’t appear to provide any additional insight beyond PET/CT for thoracic staging of non-small cell lung cancer, according to a study published Feb. 6 in the Journal of Nuclear Medicine.

Three major patient advocacy associations, the Alzheimer’s Association, the Michael J. Fox Foundation and the W. Garfield Weston Foundation, have joined forces to encourage researchers to explore the biological bridges between Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

The global market for medical reagents, including those used for molecular imaging purposes, is expected to grow substantially through 2016, according to a market report announced Feb. 5 from research firm TechNavio.